Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

MK-3475A

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 17, 2026 · PHASE 3 TRIAL

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

ClinicalTrials.gov

Phase 3 randomized controlled trial currently recruiting with no results reported; registry record describes planned design and endpoints only.

PreliminaryNCT07431827 Merck Sharp & Dohme MK-3475A

Reported

Planned enrollment400

PhasePhase 3

Primary endpointDisease-free Survival (DFS), up to ~11 years

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support